A PHASE 1/2, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION, DOSE EXPANSION, AND SINGLE REPEAT DOSE STUDY OF TSRA-196 IN ADULTS WITH THE PIZZ GENOTYPE WHO HAVE LUNG AND/OR LIVER DISEASE ASSOCIATED WITH SEVERE ALPHA-1 ANTITRYPSIN DEFICIENCY

Registry ID

TSRA196-AAT-201

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

TESSERA THERAPEUTICS, INC.

Last update

2026-05-07

Conditions

• LUNG DISEASE
• LIVER DISEASE

Related clinical trials

• A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK4532990 FOR STEATOHEPATITIS IN ADULTS WITH ALCOHOL RELATED LIVER DISEASE (ALD)
• AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH FIBROTIC LUNG DISEASE
• REDUCING RESPIRATORY SYMPTOMS OF PULMONARY IRRADIATION IN INTERSTITIAL LUNG DISEASE (RESPIRE-ILD): A 2X2 FACTORIAL RANDOMIZED PHASE II TRIAL TESTING N-ACETYL CYSTEINE AND DEXAMETHASONE
• EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER DISEASE
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FAZIRSIRAN IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE WITH METAVIR STAGE F1 FIBROSIS
• PIONEERING PRE- AND POST-OPERATIVE INTEGRATIVE CARE TO IMPROVE THORACIC CANCER QUALITY OF CARE: THE THORACIC PERI-OPERATIVE INTEGRATIVE SURGICAL CARE EVALUATION (POISE) TRIAL - STAGE III

View on source registry